Analyst Upgrades

• Marriott (MAR) to outperform from market perform at Wells Fargo.
• Quest Diagnostics (DGX) and Owens-Illinois (OI) to outperform from neutral at Credit Suisse.
• FirstMerit (FMER) to outperform from perform at Oppenheimer.
• Safeway (SWY) to hold from sell at Citigroup.
• Babcock & Wilcox (BWC) to buy from neutral, as well as Jacobs Engineering (JEC) and W. R. Berkley (WRB) to neutral from sell, at Goldman.
• Pioneer Natural (PXD) to overweight from equal weight at Barclays.
• Teekay Tankers (TNK) to buy from underperform at BofA/Merrill.

Analyst Upgrades

• Home Depot (HD) to buy from neutral at Goldman.
• Delta Air Lines (DAL) to buy from neutral at BofA/Merrill.
• Heico (HEI) to outperform from sector perform at RBC Capital.
• Royal Dutch Shell (RDS.A) to outperform from neutral at Credit Suisse.
• MB Financial (MBFI) to outperform from neutral at RW Baird.
• Quest Diagnostics (DGX) to equal weight from underweight at Morgan Stanley.
• Oshkosh (OSK) to neutral from underweight at JPMorgan.
• Volterra (VLTR) and Silicon Laboratories (SLAB) to buy from neutral at Roth Capital.
• Ascena Retail Group (ASNA) to overweight from neutral at Piper Jaffray.
• Cytec Industries (CYT) to buy from hold at Deutsche Bank.

Analyst upgrades:

• Verizon (VZ) to conviction buy from buy at Goldman.
• CSX (CSX) to outperform from market perform at Wells Fargo.
• AK Steel (AKS) to overweight from neutral, as well as Lorillard (LO) and Fifth Third Bancorp (FITB) to neutral from underweight, at JPMorgan.
• Marathon Oil (MRO) to overweight from equal weight at Morgan Stanley.
• Corning (GLW) to buy from outperform at CLSA.
• Quest Diagnostics (DGX) to buy from hold at Jefferies and to outperform from sector perform at RBC Capital.
• Salesforce.com (CRM) to buy from neutral at Roth Capital.
• Baker Hughes (BHI) to buy from hold at Weeden and to outperform from neutral at Macquarie.
• Western Digital (WDC) and Seagate (STX) to buy from underperform at BofA/Merrill.

Analyst Upgrades

• Diamond Offshore (DO) to conviction buy from sell and Baker Hughes (BHI) to buy from neutral at Goldman.
• Frontier Communications (FTR) to outperform from market perform at Wells Fargo.
• Syntel (SYNT) to outperform from market perform at Wells Fargo, to buy from hold at Deutsche Bank and to buy from neutral at Janney Capital.
• Kulicke & Soffa (KLIC) and Fiserv (FISV) to outperform from perform at Oppenheimer.
• 3M (MMM) to neutral from underweight and Tyco (TYC) to overweight from neutral at JPMorgan.
• Collective Brands (PSS) and Nordstrom (JWN) to overweight from equal weight, as well as Foot Locker (FL) to equal weight from underweight, at Morgan Stanley.
• Amazon.com (AMZN) to buy from hold at Lazard Capital.
• Yamana Gold (AUY) to outperform from neutral at Credit Suisse.

Over the past week, the medical diagnostic instrument market has heated up. On Friday, there was a report that Beckman Coulter (BEC) was seeking a buyer. On the news, the shares spiked 27%

Now there may be another deal. Genoptix (GXDX), which develops cancer testing equipment, appears to also be on the selling block. It looks like the process is in its early stages.

Analyst Upgrades

• Goldman upgraded Walmart (WMT) to buy from neutral, citing compelling valuation, margin expansion and expense control. The firm has a $60 target on the stock.
• FBR Capital upgraded Urban Outfitters (URBN) to outperform from market perform on valuation and its belief that sustainable positive comp trends will return in 2010. The firm maintains a $35 price target on shares.
• JPMorgan upgraded Manpower (MAN) to overweight from neutral. The firm cites valuation and improving temp fundamentals in the U.S. and France for the upgrade and has a $70 price target on the stock.
• Arena Resources (ARD) was upgraded to buy from neutral at SunTrust.
• C.R. Bard (BCR) was upgraded to neutral from underweight at Piper Jaffray.
• Cardinal Health (CAH) was upgraded to overweight from market weight at Thomas Weisel.

The nation is on the cusp of historic and civilization-advancing change with the upcoming health care reform bill, and that change bodes well for Quest Diagnostics (NYSE: DGX), which is why I'm reiterating my Buy rating for the company, first recommended on June 25, 2009, at a price of $55.89.

Quest's positive story remains the same: diagnostic tests are at the core of health care services, and even though the number of tests per citizen will likely decline in the years ahead, when one adds 30-45 million more citizens regularly accessing health care services annually, within 10 years, the probability of increased business is high, to say the least.

The earnings crunch begins in earnest this week, and analysts surveyed by Thomson Reuters are expecting a parade of companies reporting profit declines in the just completed quarter. That includes more financials, such as American Express Co. (NYSE: AXP), Bank of New York Mellon Corp. (NYSE: BK), M&T Bank Corp. (NYSE: MTB), Northern Trust Corp. (NASDAQ: NTRS), State Street Corp. (NYSE: STT), US Bancorp (NYSE: USB), and Wells Fargo & Co. (NYSE: WFC). On the other hand, Capital One Financial Corp. (NYSE: COF), E*Trade Financial Corp. (NASDAQ: ETFC), Regions Financial Corp. (NYSE: RF), and Zions Bancorp. (NASDAQ: ZION) are expected to post losses.

This week's anticipated earnings decliners also include tech companies such as Apple Inc. (NASDAQ: AAPL), Lexmark International Inc. (NYSE: LXK), Microsoft Corp. (NASDAQ: MSFT), Qualcomm Inc. (NASDAQ: QCOM), Texas Instruments Inc. (NYSE: TXN), and Yahoo! Inc. (NASDAQ: YHOO). Advanced Micro Devices Inc. (NYSE: AMD) is expected to post a loss.

Analyst upgrades:

• Merriman upgraded Dendreon (NASDAQ: DNDN) to Buy from Neutral on expectations shares will react positively to the full IMPACT data release on April 28. The firm thinks Provenge could represent the first cancer immunotherapy approved in the U.S. and raised its valuation range on the stock to $33-$34 from $18-$19.
• Piper Jaffray upgraded Andersons (NASDAQ: ANDE) as it believes the valuation is attractive, investor expectations are low, and the company's fertilizer and rail segments could recovery in FY10. The firm has a $19 target on shares. Goldman upgraded the auto sector to Neutral from Cautious and added Ford (NYSE: F) to its Conviction Buy list. The analyst does not believe Ford will have to declare bankruptcy and sees the company benefiting from Chrysler share declines and GM's (NYSE: GM) reduced product offerings. Ford's price target is $6
• Banc of America/Merrill upgraded U.S. Airways (NYSE: LCC) to Buy from Underperform.
• Broadcom (NASDAQ: BRCM) was upgraded to Equal Weight from Underweight at Morgan Stanley.
• Caterpillar (NYSE: CAT) was raised to Overweight from Neutral at JP Morgan.

• Merriman upgraded Taser (NASDAQ: TASR) to Buy from Neutral as it believes current valuation levels do not reflect the company's market opportunities and that the law enforcement funding in President Obama's stimulus plan will boost sales in Q4 and FY10.
  
• Goldman upgraded Macy's (NYSE: M) to Buy from Neutral and added shares to its Conviction Buy List based on reduced balance sheet concerns and improved risk/reward. The firm also raised their target to $8.25 from $8.
  
• JP Morgan upgraded Family Dollar (NYSE: FDO) to Neutral from Underweight and raised its target to $29 from $19 following the better-than-expected Q2 report. The analyst continues to prefer Dollar Tree (NASDAQ: DLTR) and Wal-Mart (NYSE: WMT).
• Goldman removed Universal Am (NYSE: UAM) from the Conviction Sell List.
  
• McDermott (NYSE: MDR) was upgraded to Buy from Hold at Jefferies.
  
• Canadian Natural (NYSE: CNQ) was upgraded to Sector Outperformer from Sector Performer at CIBC.

• Baird upgraded MSM Industrial (NYSE: MSM) to Outperform from Neutral based on valuation and a positive view for Industrial Distributors.
  
• William Blair upgraded Allscripts (NASDAQ: MDRX) to Outperform from Market Perform on valuation following the recent pullback and believes Allscripts is well positioned to benefit from public policy that drives adoption of electronic medical records.
  
• Citigroup upgraded Consolidated Edison (NYSE: ED) to Buy from Hold as they believe the ALJ recommendation in the company's pending electric rate case indicates potential for an improving outlook.
• Raytheon (NYSE: RTN) was raised to Buy from Neutral at Goldman.
  
• Smith & Nephew (NYSE: SNN) was upgraded at JP Morgan to Neutral from Underweight.
  
• Becton Dickinson (NYSE: BDX) was upgraded to Overweight from Equal Weight at Morgan Stanley.

• Oppenheimer downgraded Bio-Reference Labs (NASDAQ: BRLI) to Perform from Outperform as they believe weaker volumes could pressure top-line growth in the near-term. The firm lowered their target to $25 from $30.
  
• Morgan Stanley downgraded shares of Alcatel-Lucent (NYSE: ALU) to Equal Weight from Overweight to reflect market deterioration as they find the risk/reward as balanced at current levels.
  
• JP Morgan cut Nestle (OTC: NSRGY) to Underweight from Neutral on concerns the company's 2009 revenue will miss consensus estimates due to market share losses.
• Rio Tinto (NYSE: RTP) and Anglo American (NASDAQ: AAUK) were lowered to Hold from Buy at Deutsche Bank.